ViRexx Appoints Directors And Vice President, Drug Development; Company Also Appoints Corporate Consultant and Investor Relations Consultant for US and Europe.

Business Editors

EDMONTON, Alberta--(BUSINESS WIRE)--April 15, 2004

ViRexx Medical Corp. (TSX Venture: VIR) ("ViRexx") is pleased to announce the appointments of Dr. Irwin Griffith as Vice President, Drug Development, Mr. Douglas Gilpin and Dr. Jean Claude Gonneau to the Board of Directors, Mr. Kenneth David Stevenson as a corporate consultant and Mr. Howard Appel as an investor relations consultant.

Dr. Antoine Noujaim, President and CEO of ViRexx commented, "Dr. Griffith's extensive experience in all aspects of product development will be invaluable as ViRexx continues to advance its HepaVaxx B and HepaVaxx C therapeutic vaccines for the treatment of chronic hepatitis B and C. The addition of Mr. Gilpin and Dr. Gonneau to the Board of Directors, Mr. Stevenson as corporate consultant and Mr. Appel as investor relations consultant solidify ViRexx's senior team and will help our Company to continue its success."

Dr. Irwin Griffith has more than 15 years of expertise in the development and commercialization of immunotherapies for cancer, inflammatory and autoimmune diseases. He previously served as Senior Director for Business Development with Biomira Inc. prior to founding Rational BioDevelopment Inc. in 2003.

Dr. Jean Claude Gonneau is currently the General Manager of SG Cowen, Europe SAS, an investment banking institution. He has more than 25 years experience working in the financial markets in Europe and North America and maintains responsibility for the European operations of SG Cowen. Prior to his appointment as General Manager, he was Managing Director of SG Cowen. Dr. Gonneau is a director of numerous publicly traded companies and lives in Paris, France.

Mr. Douglas Gilpin is a Chartered Accountant with more than 30 years of business advisory and consultancy experience. He was a partner with KPMG LLP from 1981 until his retirement from the firm in 1999. His practice focused on business advisory and assurance and involved work with numerous companies in the biotechnology field. Mr. Gilpin is actively involved as a volunteer for Junior Achievement, the Heart & Stroke Fund and the Canadian Cancer Society.

Mr. Appel is a seasoned investor relations professional who will provide investor relations services which are designed to build the Company's profile and exposure in the United States and Europe. Mr. Stevenson will advise ViRexx on strategic partnership strategies, possible technology acquisitions and carry out general corporate duties for the benefit of ViRexx in Europe.

The Board of Directors has granted Dr. Griffith, Mr. Gilpin and Dr. Gonneau options (100,000, 125,000 and 125,000 respectively) to purchase shares of the Company. Mr. Stevenson has been granted 100,000 options. As part of the Company's investor relations strategy, Mr. Appel and The Equicom Group Inc. have been granted options (400,000 and 40,000 respectively) to purchase shares of the Company. All options issued to consultants have been granted in accordance with TSX Venture policies. In addition, several employees of ViRexx have been granted 290,000 options to purchase shares of the Company. All options have an exercise price of $0.80 per share. The decision to grant these options will be presented for ratification to the shareholders of ViRexx at the Annual General Meeting to be held on June 17, 2004.

About ViRexx

ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel and unique therapeutic products for the treatment of chronic Hepatitis B, Hepatitis C and selected solid tumors. For additional information, please visit www.virexx.com.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Venture Exchange has not approved or disapproved of the information contained herein.